Tag Archives: gild

Facebook Among IBD 50’s Top 5 Earnings Kings In 2014

Massive EPS gains one year might mean that a company tops out the next. While the five IBD 50 stocks in today’s screen are set to show 2014 EPS growth that leaves 2013 in the dust, the years beyond might not be as bountiful. Shares of Gilead Sciences (GILD) have launched upward since its hepatitis C drug Sovaldi debuted last year. The company’s full-year 2014 EPS is expected to grow 290% year over year to $7.95, partly on Sovaldi and Harvoni —

AbbVie’s Hep C Regimen OK’d, 12-Week Cost $83,319

AbbVie’s hepatitis C regimen won FDA approval Friday, becoming the second entrant in what is already a huge market for interferon-free HCV treatments. The Viekira Pak will cost $83,319 for 12 weeks, in line with forecasts and undercutting Gilead Sciences’ (GILD) $94,500 for the same treatment length. The AbbVie (ABBV) regimen consists of three drugs: ombitasvir, paritaprevir (first developed by Enanta Pharmaceuticals (ENTA) and

Stock Movers: Why These 5 Top Stocks Are Rising Today

Here is why shares of biotech Gilead Sciences (GILD) and three four other highly rated stocks are rallying in heavy volume today. Gilead began running up in premarket trading after drug giant Merck (MRK) said Sunday it would not move forward with development of a drug combination aimed at shortening treatment time for hepatitis C, citing disappointing clinical data. The treatment would have used Gilead’s Sovaldi, but also would compete with the